This invention relates to effecting pathological changes in subcutaneous histological features so as to eliminate unsightly or potentially harmful vascular and cellular conditions, without side effects and with fewer steps and less discomfort than has heretofore been possible.
Radiation therapy is an accepted treatment for a wide variety of medical conditions. High intensity radiant energy sources in the visible band, such as lasers, are now being widely used for both internal and extracorporeal procedures. While the microwave band, between 300 MHz and 30 GHz affords the capability of penetrating deeper than visible light while interacting differently with body tissue it has heretofore been employed primarily only in a variety of dissimilar medical procedures.
Microwave energy exerts its effect on tissue through controlled regional heating (hyperthermia) of affected features through interaction between the wave energy and magnetically polarizable tissue matter. By using microwaves to establish a regional hyperthermia, it is possible to preferentially increase the temperature of diseased or unwanted histological features to levels which are pathologically effective. At the same time, a necessary objective is to maintain adjacent tissue at acceptable temperatures, i.e., below the temperature at which irreversible tissue destruction occurs. Such microwave induced hyperthermia is well known in the field of radiology where it is used in the treatment of individuals with cancerous tumors.
A number of specific methods for treating histological features by the application of microwave radiation are described in the medical literature. For example, a technique for treating brain tumors by microwave energy is disclosed in an article entitled “Resection of Meningiomas with Implantable Microwave Coagulation” in Bioelectromagnetics, 17 (1996), 85-88. In this technique, a hole is drilled into the skull and a catheter is invasively inserted into the hole to support a coaxial radiator or antenna. Microwave energy is then applied to the antenna to cause the brain tumor to be heated to the point where the center of the tumor shows coagulative necrosis, an effect which allows the meningioma to be removed with minimal blood loss. Another technique in which microwave energy is utilized to treat prostate conditions is disclosed by Hascoet et al in U.S. Pat. No. 5,234,004. In this technique, a microwave antenna in a urethral probe connected to an external microwave generating device generates microwaves at a frequency and power effective to heat the tissues to a predetermined temperature for a period of time sufficient to induce localized necrosis. In a related technique disclosed by Langberg in U.S. Pat. No. 4,945,912, microwave energy is used to effect cardiac ablation as a means of treating ventricular tachycardia. Here, a radiofrequency heating applicator located at the distal end of a coaxial line catheter hyperthermically ablates the cardiac tissue responsible for ventricular tachycardia. As with the described methods of tumor treatment, this method of cardiac ablation operates by preferentially heating and destroying a specifically targeted area of tissue while leaving surrounding tissue intact.
While the general principle of propagating microwave energy into tissue for some therapeutic effect is thus known, such applications are usually based on omnidirectional broadcasting of energy with substantial power levels. The potential of microwave energy for use with subcutaneous venous conditions and skin disorders has not been addressed in similar detail, probably because of a number of conflicting requirements as to efficacy, safety, ease of administration and side effects.
As a significant number of individuals suffer from some type of subcutaneous but visible abnormality, therapeutic techniques which effectively address these conditions can be of great value. Such features which are potentially treatable by microwave energy include conditions such as excessive hair growth, telangiectasia (spider veins) and pigmented lesions such as café-au-lait spots and port wine stains (capillary hemangiomas). Of these conditions, excessive hair growth and spider veins are by far the most common, affecting a large percentage of the adult population.
Unwanted hair growth may be caused by a number of factors including a genetic predisposition in the individual, endrocrinologic diseases such as hypertrichosis and androgen-influenced hirsuitism as well as certain types of malignancies. Individuals suffering from facial hirsuitism can be burdened to an extent that interferes with both social and professional activities and causes a great amount of distress. Consequently, methods and devices for treating unwanted hair and other subcutaneous histological features in a manner that effects a permanent pathological change are very desirable.
Traditional treatments for excessive hair growth such as depilatory solutions, waxing and electrolysis suffer from a number of drawbacks. Depilatory solutions are impermanent, requiring repeated applications that may not be appropriate for sensitive skin. Although wax epilation is a generally safe technique, it too is impermanent and requires repetitive, often painful repeat treatments. In addition, wax epilation has been reported to result in severe folliculitis, followed by permanent keloid scars. While electrolysis satisfactorily removes hair from individuals with static hair growth, this method of targeting individual hairs is both painful and time consuming. In addition, proper electrolysis techniques are demanding, requiring both accurate needle insertion and appropriate intensities and duration. As with wax epilation, if electrolysis techniques are not performed properly, folliculitis and scarring may result.
Recently developed depilatory techniques, utilizing high intensity broad band lights, lasers or photochemical expedients, also suffer from a number of shortcomings. In most of these procedures, the skin is illuminated with light at sufficient intensity and duration to kill the follicles or the skin tissue feeding the hair. The impinging light targets the skin as well as the hair follicles, and can burn the skin, causing discomfort and the potential for scarring. Further, laser and other treatments are not necessarily permanent and may require repeated applications to effect a lasting depilation.
Like hair follicles, spider veins are subcutaneous features. They exist as small capillary flow paths, largely lateral to the skin surface, which have been somewhat engorged by excessive pressure, producing the characteristic venous patterns visible at the skin surface. Apart from the unsightly cosmetic aspect, telangiecstasia can further have more serious medical implications. Therefore, methods and devices for treating spider veins and other subcutaneous histological features in a manner that effects a permanent pathological change to the appropriate tissues are highly desirable.
The classical treatment for spider veins is sclerotherapy, wherein an injection needle is used to infuse at least a part of the vessel with a sclerotic solution that causes blood coagulation, and blockage of the blood path. With time, the spider veins disappear as the blood flow finds other capillary paths. Since there can be a multitude of spider veins to be treated over a substantial area, this procedure is time-consuming, tedious, and often painful. It also is of uncertain effectiveness in any given application and requires a substantial delay before results can be observed.
Another procedure for the treatment of shallow visible veins, which is similar to techniques used in depilation, involves the application of intense light energy for a brief interval. This technique exposes the skin surface and underlying tissue to concentrated wave energy, heating the vein structure to a level at which thermocoagulation occurs. In particular, these energy levels are so high that they cause discomfort to some patients, and they can also be dangerous to those in the vicinity, unless special precautions are taken. In addition, some patients can be singed or burned, even though the exposure lasts only a fraction of a second.
Due to the serious problems that the subcutaneous abnormalities can create in individuals, there is a general need to be able to treat such features in a manner that effects beneficial pathological change without adverse side effects or discomfort. An optimal therapeutic technique should effect a permanent pathological change without requiring repeated applications to reach the desired effect. Moreover, these procedures should be noninvasive, should cover a substantial target area that is not limited to a single hair follicle or spider vein, and should make optimum use of the energy available. Finally, pathological changes should occur only in the targeted feature, and not in intervening or underlying layers.
The present invention overcomes the deficiencies in previously described methods for treating subcutaneous features by delivering a dosage of microwave energy that is maintained for only a short duration but at an energy level and at a wavelength chosen to penetrate to the depth of a chosen histological feature. The subcutaneous features are destroyed or pathologically altered in a permanent fashion by the hyperthermic effect of the wave energy while the surrounding tissue is left intact.
In accordance with the invention, the effective delivery of microwave energy into the subcutaneous feature can be maximized in terms of both the percentage of energy transmitted into the body and a preferential interaction with the target feature itself. The microwave energy is specifically targeted to the chosen depth and the targeted feature is heated internally to in excess of about 55° C., to a level which thromboses blood vessels and destroys hair follicles. The ability to target a wide area containing a number of features simultaneously enables a single procedure to supplant or reduce the need for repetitive applications.
Methods in accordance with the invention utilize certain realizations and discoveries that have not heretofore been appreciated in relation to wave energy-tissue interactions at a substantial depth (up to 5 mm below the skin surface). The wavelengths that are selected are preferentially absorbed by a targeted feature such as a blood vessel more readily than by skin surface and tissue. Thus, a chosen frequency, such as 14 GHz, penetrates through surface tissue to the chosen depth of the target feature, but not significantly beyond, and the energy heats the target more than adjacent tissue. Dynamic thermal characteristics are also taken into account, because transfer of thermal energy from small target features such as minute heated blood vessels to the surrounding tissue (the “thermal relaxation time”) is much faster than that for larger vessels. The duration of a dosage, typically in the range of 100 milliseconds, is varied to adjust for this size factor.
Immediately prior to, concurrently with, or after the application of penetrating microwave energy, the skin surface is advantageously cooled. This cooling may be effected in a number of ways such as through the delivery, as rapidly expanding gas, of known coolants into a small space between the microwave emitter and the skin surface. The use of coolant enables the surgeon not only to minimize patient discomfort and irritation, but also to adjust energy dosages in terms of intensity and duration, because heat extraction at the surface also affects heating to some depth below the surface. The surgeon can also employ air cooling to minimize irritation while assuring results over a larger subcutaneous area and with fewer applications.
While it is advantageous to cool the skin surface with a separate medium in the target area immediately prior to or during wave energy application, it is also shown that the wave energy emitting device itself can be used to draw thermal energy off the skin surface. Again, the skin is heated minimally, giving the patient little, if any discomfort, and avoiding skin irritation. Comfort may be ensured for sensitive patients by a topical anesthetic, or by a conductive gel or other wave energy complementary substance introduced between the applicator and the skin surface.
The energy applied is generally in excess of about 10 Joules, and the duration is typically in the range of 0.10 to 1,000 milliseconds, with about 100 milliseconds being most used. The total energy delivered is typically in the range of 10-30 Joules, although the energy delivered as well as frequency may be changed in accordance with the nature of the targeted features, the target volume and depth. In a depilation process, for example, 10 to 20 Joules will usually suffice when a compact applicator is used, while a higher input level, such as 20 to 30 Joules, is used for a telangiectasia treatment.
A system in accordance with the invention for use in such procedures may employ a tunable power generator, such as a tunable power source operable in the microwave range from 2.45 GHz to 18 GHz, and means for gating or otherwise controlling the power output to provide selected pulse durations and energy outputs. The system also can incorporate power measurement sensors for both forward power and reflected power or circuits for measuring impedance directly. Thereby, tuning adjustments can be made to minimize reflection. Power is delivered through a manipulatible line, such as a flexible waveguide or coaxial line, to a small and conveniently positionable applicator head which serves as the microwave launcher or emitter. The applicator head may advantageously include, in the wave launching section, a dielectric insert configured to reduce the applicator cross-section, and to provide a better match to the impedance of the skin surface. Furthermore, the dielectric insert is chosen so as to distribute the microwave energy with more uniform intensity across the entire cross section, thus eliminating hot spots and covering a larger area.
If the dielectric is of a material, such as boron nitride or beryllium oxide, which is a good thermal conductor, it can be placed in contact with the skin and thermal energy can be conducted away from the skin as microwave energy is transferred. Different clinical needs can be met by making available a number of different dielectric element geometries fitting within an interchangeable mount. The applicator head may further include a pressure limiting mechanism to insure that the head does not compress vessels as the procedure is being carried out.
In addition to the range of capabilities thus afforded, the surgeon can use ultrasound or other inspection techniques to identify the locations of the subcutaneous features for the precise mapping of target sites. Using an indexing or aiming device or element on the applicator head, energy can be applied a minimum number of times at precise locations to encompass a maximum number of targets. Because skin and tissue characteristics vary, pretesting target characteristics and varying the frequency or phase applied can increase efficiency and reduce the possibility of side effects.
In another application in accordance with the invention, the skin target area may be more readily visualized by using a microwave launcher positionable within an end unit in one of two alternate positions. In one position, the target area can be viewed and the launcher indexed for movement into precise proximity to the target area. In yet another example, a rectangular waveguide of standard size and therefore larger cross-section is used, with air cooling of the skin surface. For depilation, a peel-off, attachable label locating a number of delineated contiguous target areas can be placed on the skin. When the applicator has been energized at each target area, the label sheet can be peeled off, removing hair residue with it.
The applications of the process and method are not limited to conditions such as spider veins and unwanted hair, but further encompass pigmented lesions and related abnormalities, as well as other temporary and permanent skin disorders.
A better understanding of the invention may be had by reference to the following specification, taken in conjunction with the accompanying drawings, in which:
A system in accordance with the invention, referring now to
Referring to
Preinspection of the target site is dependent on the nature of the target. Although visual inspection is sometimes alone sufficient for target area selection, as with hirsuitism, target veins at depth below the surface can often better be identified, located, and dimensioned by conventional analytical instruments, such as those using ultrasound imaging. As is described hereafter, the power, duration and frequency applied can also be adjusted in relation to the thermal relaxation characteristics of a target blood vessel, which in turn is dependent on size and location.
A microwave transmission line 24, here including a flexible rectangular waveguide or a flexible coaxial section 26 that may be manually manipulated, supplies the microwave energy through a phase shifter or other kind of tuner 27 to a hand applicator 30 shown here as positioned against a limb 32 exposed within a surgical drape 34. The handpiece 30, shown in greater detail in
The flexible coaxial line 26 allows a surgeon to move the applicator 30 to place its open end manually wherever desired on the body surface 32. At the frequency range of 12-18 GHz, a standard WR 62 waveguide section with 0.622″×0.311″ orthogonal dimensions can be employed at the output end of the impedance matching section 36. The tapered section 38, loaded by the dielectric 44 in this example, reduces the waveguide dimension to 0.250″×0.150″ at the output terminal face 40. The end face 40, however, is set off from the limb or other body surface 32 against which it is juxtaposed by an encompassing and intervening spacer element 54, best seen in
Other alternative approaches may be utilized to minimize discomfort and, separately or additionally, provide improved efficiency. A compound that is complementary to the delivery of the microwave energy, in the sense of neither being reflective or absorptive, and therefore not appreciably heated, can be placed on the skin prior to microwave pulse application. For example, a topical anesthetic having short term effectivity may be all that is needed to reduce the discomfort of some patients to an acceptable level. Other patients may require no coolant or topical anesthetic whatsoever. Another alternative is to employ a surface gel or other substance that improves impedance matching between the microwave pulse launching device and the surface tissues.
The microwave delivery system provided by the applicator 30 delivers microwave energy over an advantageously broad field distribution into a subcutaneous surface area as best understood by reference to
In accordance with the present invention, advantage is taken of the results of an analysis of the interaction of microwaves with biological tissues at different frequencies. The complex permittivity ∈* of any given matter, including biological matter, in a steady state field is conventionally analyzed using the following equation:
∈*=∈0(∈′−∈″),
in which ∈0 is the dielectric constant of free space and the real component, ∈′, is the dielectric constant, while the imaginary component, ∈″ is the loss factor. As seen in
The structure of skin is somewhat idealistically and simplistically depicted in
With these considerations in mind, appreciation of the operation of the system of
When the control pulse circuits 16 operate, they first provide a control impulse to open the solenoid valve 64, in this example, and then turn on the traveling wave tube system 12 for the selected interval. Because the valve requires a few milliseconds (e.g., 20 to 35) to operate and a few milliseconds are also needed for the pressurized coolant from the source 60 to pass through the outer conduit 62 and the side conduit 58 in the spacer 54, it is preferred to delay the microwave pulse until cooling has actually begun or is contemporaneously begun. Alternatively, as previously noted, a temperature sensor 68 that detects a temperature drop at the skin surface may be used to either trigger the microwave pulse or to preclude its operation until after the coolant has become effective.
For depilation, pulses in the range of 10 to 20 Joules in terms of total work output have been shown to effect permanent depilation without significant discomfort or significant adverse side effects. Tests were run using the dielectric loaded applicator 30 having a 0.250″×0.150″ output area (5 mm×3 mm, or 15 mm2), and employing a pulse duration of 100 milliseconds in all instances. A substantial number of experiments were run on test rabbits with this applicator, varying only the power applied so as to change the total energy in Joules. The results were examined by a pathologist and the accompanying Tables 1 and 2, appended following the specification, show the results of his examination.
The system of
Pathological examination of these animal studies consistently demonstrated destruction of hair follicles over a wide range of microwave energy levels. The destruction extended to the base of the follicle, which is significant to permanent hair removal. The amount of hair destruction within the target area varies in accordance with the total amount of energy, but destruction is substantially complete at 14 Joules and higher. Furthermore, until the energy delivered is in excess of 20 Joules, the appearance of the skin is normal in all cases and the epidermis is histologically intact. Minor indications of dermal fibrosis are not indicative of clinical scar formation. Minor vascular changes, such as intimal fibrosis of small arteries, constitute neither damaging nor permanent conditions. Consequently, a dosage in the range of 14 to 20 Joules is found both to be effective and to be free of deleterious side effects.
The effects of delivery of microwave energy, with surface cooling, are illustrated graphically in
The microwave energy does not significantly penetrate beyond the depth of the targeted histological features because of attenuation, the limitation on total energy delivered and the lower loss factor in tissue.
Where the histological defects are benign vascular lesions, as with the telangiectasia condition, different tests and operating conditions may be employed, as shown in the steps of
The pulse duration is a significant parameter in relation to the vessel diameter, since the smaller the vessel diameter, the shorter is the thermal relaxation time. Even though the loss factor of blood is higher than that of the tissue, dissipation of heat to surrounding tissue is much faster with a small blood vessel and consequently shorter term heating is needed. As seen in
Consequently, when the microwave pulse is delivered, the subcutaneous target is heated to the range of 55° C. to 70° C., sufficient to thrombose the vascular structure and terminate flow permanently. The specific nature contributing factors to disappearance of the vessels with time may be one or more factors, including thermocoagulation of the blood itself, heating of the blood to a level which causes thrombosis of the vessel or some other effect. The net result, however, is that a fibrous structure forms in the vessel which clogs and terminates flow, so that the resultant fibrous structure is reabsorbed with time, as new capillary flow paths are found. In any event, heating in the 55° C. to 70° C. is sufficient to effect (step 96) the permanent pathological change that is desired (step 98).
An alternative applicator that covers a larger area and is employed with a peelable indicia label as shown in
With the arrangement of
It should be noted, furthermore, that a standard open rectangular waveguide can be loaded with dielectric elements in a manner which enables size to be reduced without restricting coolant flow.
Another alternative that may be used, but is not shown in the figures, relates to a modification of the spacer element that is employed in the example of
A different approach to a useful applicator is shown in
In addition, a target mark placed on the skin surface by the surgeon may be viewed by a system including a fiber optic line 145 that extends through the dielectric 130 and leads via a flexible fiber optic line 147 to an image viewing system 149.
In use, this applicator 120 of
Although a number of forms and modifications in accordance with the invention have been described, it will be appreciated that the invention is not limited thereto, but encompasses all forms and expedients in accordance with the appended claims.
This application is a divisional of application(s) Ser. No. 08/904,175 filed on Jul. 31, 1997 now U.S. Pat. No. 6,104,959.
Number | Name | Date | Kind |
---|---|---|---|
2407690 | Southworth | Sep 1946 | A |
3307553 | Liebner | Mar 1967 | A |
3527227 | Fritz | Sep 1970 | A |
3693623 | Harte et al. | Sep 1972 | A |
3845267 | Fitzmayer | Oct 1974 | A |
4069827 | Dominy | Jan 1978 | A |
4095602 | Leveen | Jun 1978 | A |
4108147 | Kantor | Aug 1978 | A |
4140130 | Storm | Feb 1979 | A |
4174713 | Mehl | Nov 1979 | A |
4190053 | Sterzer | Feb 1980 | A |
4190056 | Tapper et al. | Feb 1980 | A |
4197860 | Sterzer | Apr 1980 | A |
4228809 | Paglione | Oct 1980 | A |
4375220 | Matvias | Mar 1983 | A |
4378806 | Henley-Cohn | Apr 1983 | A |
4397313 | Vaguine | Aug 1983 | A |
4397314 | Vaguine | Aug 1983 | A |
4446874 | Vaguine | May 1984 | A |
4528991 | Dittmar et al. | Jul 1985 | A |
4589424 | Vaguine | May 1986 | A |
4597379 | Kihn et al. | Jul 1986 | A |
4617926 | Sutton | Oct 1986 | A |
4641649 | Walinsky et al. | Feb 1987 | A |
4669475 | Turner | Jun 1987 | A |
4672980 | Turner | Jun 1987 | A |
4690156 | Kikuchi et al. | Sep 1987 | A |
4744372 | Kikuchi et al. | May 1988 | A |
4747416 | Kikuchi et al. | May 1988 | A |
4800899 | Elliott | Jan 1989 | A |
4841989 | Kikuchi et al. | Jun 1989 | A |
4841990 | Kikuchi et al. | Jun 1989 | A |
4860752 | Turner | Aug 1989 | A |
4860770 | Kikuchi et al. | Aug 1989 | A |
4873995 | Kikuchi et al. | Oct 1989 | A |
4881543 | Trembly et al. | Nov 1989 | A |
4891483 | Kikuchi et al. | Jan 1990 | A |
4945912 | Langberg | Aug 1990 | A |
4974587 | Turner et al. | Dec 1990 | A |
5025810 | Kikuchi et al. | Jun 1991 | A |
5033478 | Kikuchi et al. | Jul 1991 | A |
5059192 | Zaias | Oct 1991 | A |
5097846 | Larsen | Mar 1992 | A |
5101836 | Lee | Apr 1992 | A |
5107832 | Guibert et al. | Apr 1992 | A |
5143063 | Fellner | Sep 1992 | A |
5148814 | Kikuchi et al. | Sep 1992 | A |
5186181 | Franconi et al. | Feb 1993 | A |
5190031 | Guibert et al. | Mar 1993 | A |
5190518 | Takasu | Mar 1993 | A |
5198776 | Carr | Mar 1993 | A |
5226907 | Tankovich | Jul 1993 | A |
5231997 | Kikuchi et al. | Aug 1993 | A |
5234004 | Hascoet et al. | Aug 1993 | A |
5246438 | Langberg | Sep 1993 | A |
5272301 | Finger et al. | Dec 1993 | A |
5295955 | Rosen et al. | Mar 1994 | A |
5301692 | Knowlton | Apr 1994 | A |
5305748 | Wilk | Apr 1994 | A |
5315994 | Guibert et al. | May 1994 | A |
5316000 | Chapelon et al. | May 1994 | A |
5364336 | Carr | Nov 1994 | A |
5364394 | Mehl | Nov 1994 | A |
5383917 | Desai et al. | Jan 1995 | A |
5385544 | Edwards et al. | Jan 1995 | A |
5405346 | Grundy et al. | Apr 1995 | A |
5407440 | Zinreich et al. | Apr 1995 | A |
5421819 | Edwards et al. | Jun 1995 | A |
5425728 | Tankovich | Jun 1995 | A |
5433740 | Yamaguchi | Jul 1995 | A |
5441532 | Fenn | Aug 1995 | A |
5443487 | Guibert et al. | Aug 1995 | A |
5462521 | Brucker et al. | Oct 1995 | A |
5474071 | Chapelon et al. | Dec 1995 | A |
5480417 | Hascoet et al. | Jan 1996 | A |
5503150 | Evans | Apr 1996 | A |
5507741 | L'Esperance, Jr. | Apr 1996 | A |
5507790 | Weiss | Apr 1996 | A |
5509929 | Hascoet et al. | Apr 1996 | A |
5522814 | Bernaz | Jun 1996 | A |
5531662 | Carr | Jul 1996 | A |
5540681 | Strul et al. | Jul 1996 | A |
5549639 | Ross | Aug 1996 | A |
5553612 | Lundback | Sep 1996 | A |
5569237 | Beckenstein | Oct 1996 | A |
5571154 | Ren | Nov 1996 | A |
5575789 | Bell et al. | Nov 1996 | A |
5584830 | Ladd et al. | Dec 1996 | A |
5595568 | Anderson et al. | Jan 1997 | A |
5660836 | Knowlton | Aug 1997 | A |
5662110 | Carr | Sep 1997 | A |
5683381 | Carr et al. | Nov 1997 | A |
5683382 | Lenihan et al. | Nov 1997 | A |
5690614 | Carr et al. | Nov 1997 | A |
5724966 | Lundback | Mar 1998 | A |
5732699 | Lundback | Mar 1998 | A |
5732700 | Lundback | Mar 1998 | A |
5733269 | Fuisz | Mar 1998 | A |
5735844 | Anderson et al. | Apr 1998 | A |
5743899 | Zinreich | Apr 1998 | A |
5755753 | Knowlton | May 1998 | A |
5769879 | Richards et al. | Jun 1998 | A |
5779635 | Carr | Jul 1998 | A |
5782897 | Carr | Jul 1998 | A |
5810804 | Gough et al. | Sep 1998 | A |
5814996 | Winter | Sep 1998 | A |
5824023 | Anderson | Oct 1998 | A |
5830208 | Muller | Nov 1998 | A |
5836999 | Eckhouse et al. | Nov 1998 | A |
5842985 | Lundback | Dec 1998 | A |
5871524 | Knowlton | Feb 1999 | A |
5879346 | Waldman et al. | Mar 1999 | A |
5904709 | Arndt et al. | May 1999 | A |
5919218 | Carr | Jul 1999 | A |
5919219 | Knowlton | Jul 1999 | A |
5931860 | Reid et al. | Aug 1999 | A |
5948011 | Knowlton | Sep 1999 | A |
5971982 | Betsill et al. | Oct 1999 | A |
5979454 | Anvari et al. | Nov 1999 | A |
5983124 | Carr | Nov 1999 | A |
6015404 | Altshuler et al. | Jan 2000 | A |
6026331 | Feldberg et al. | Feb 2000 | A |
6050990 | Tankovich et al. | Apr 2000 | A |
6104959 | Spertell | Aug 2000 | A |
6113593 | Tu et al. | Sep 2000 | A |
6162218 | Elbrecht et al. | Dec 2000 | A |
6171301 | Nelson et al. | Jan 2001 | B1 |
6175768 | Arndt et al. | Jan 2001 | B1 |
6181970 | Kasevich | Jan 2001 | B1 |
6197020 | O'Donnell, Jr. | Mar 2001 | B1 |
6208903 | Richards et al. | Mar 2001 | B1 |
6210367 | Carr | Apr 2001 | B1 |
6241753 | Knowlton | Jun 2001 | B1 |
6245062 | Berube et al. | Jun 2001 | B1 |
6264652 | Eggers et al. | Jul 2001 | B1 |
6273884 | Altshuler et al. | Aug 2001 | B1 |
6277104 | Lasko et al. | Aug 2001 | B1 |
6277111 | Clement et al. | Aug 2001 | B1 |
6277116 | Utely et al. | Aug 2001 | B1 |
6290699 | Hall et al. | Sep 2001 | B1 |
6306128 | Waldman et al. | Oct 2001 | B1 |
6311090 | Knowlton | Oct 2001 | B1 |
6312427 | Berube et al. | Nov 2001 | B1 |
6330479 | Stauffer | Dec 2001 | B1 |
6334074 | Spertell | Dec 2001 | B1 |
6350276 | Knowlton | Feb 2002 | B1 |
6364876 | Erb et al. | Apr 2002 | B1 |
6377854 | Knowlton | Apr 2002 | B1 |
6377855 | Knowlton | Apr 2002 | B1 |
6381498 | Knowlton | Apr 2002 | B1 |
6383182 | Berube et al. | May 2002 | B1 |
6387380 | Knowlton | May 2002 | B1 |
6405090 | Knowlton | Jun 2002 | B1 |
6413255 | Stern | Jul 2002 | B1 |
6425912 | Knowlton | Jul 2002 | B1 |
6438424 | Knowlton | Aug 2002 | B1 |
6453202 | Knowlton | Sep 2002 | B1 |
6457476 | Elmer et al. | Oct 2002 | B1 |
6470216 | Knowlton | Oct 2002 | B1 |
6471696 | Berube et al. | Oct 2002 | B1 |
6475211 | Chess et al. | Nov 2002 | B2 |
6508813 | Altshuler | Jan 2003 | B1 |
6517532 | Altshuler et al. | Feb 2003 | B1 |
6575969 | Rittman, III et al. | Jun 2003 | B1 |
6577903 | Cronin et al. | Jun 2003 | B1 |
6652518 | Wellman et al. | Nov 2003 | B2 |
6663620 | Altshuler et al. | Dec 2003 | B2 |
6682501 | Nelson et al. | Jan 2004 | B1 |
6725095 | Fenn et al. | Apr 2004 | B2 |
6743222 | Durkin et al. | Jun 2004 | B2 |
6749624 | Knowlton | Jun 2004 | B2 |
6878147 | Prakash et al. | Apr 2005 | B2 |
6887238 | Jahns et al. | May 2005 | B2 |
6887260 | McDaniel | May 2005 | B1 |
6974451 | Altshuler et al. | Dec 2005 | B2 |
6976985 | Altshuler et al. | Dec 2005 | B2 |
7004942 | Laird et al. | Feb 2006 | B2 |
7006874 | Knowlton et al. | Feb 2006 | B2 |
7022121 | Stern et al. | Apr 2006 | B2 |
7052491 | Erb et al. | May 2006 | B2 |
7077840 | Altshuler et al. | Jul 2006 | B2 |
7115123 | Knowlton et al. | Oct 2006 | B2 |
7115126 | Berube et al. | Oct 2006 | B2 |
7118590 | Cronin | Oct 2006 | B1 |
7128739 | Prakash et al. | Oct 2006 | B2 |
7141049 | Stern et al. | Nov 2006 | B2 |
7151964 | Desai et al. | Dec 2006 | B2 |
7189230 | Knowlton | Mar 2007 | B2 |
7192429 | Trembly | Mar 2007 | B2 |
7204832 | Altshuler et al. | Apr 2007 | B2 |
7229436 | Stern et al. | Jun 2007 | B2 |
7247155 | Hoey et al. | Jul 2007 | B2 |
7250047 | Anderson et al. | Jul 2007 | B2 |
7267675 | Stern et al. | Sep 2007 | B2 |
7276058 | Altshuler et al. | Oct 2007 | B2 |
7278991 | Morris et al. | Oct 2007 | B2 |
7387627 | Erb et al. | Jun 2008 | B2 |
7431719 | Altshuler et al. | Oct 2008 | B2 |
7473251 | Knowlton et al. | Jan 2009 | B2 |
7481809 | Stern et al. | Jan 2009 | B2 |
20010050083 | Marchitto et al. | Dec 2001 | A1 |
20020062124 | Keane | May 2002 | A1 |
20020062142 | Knowlton | May 2002 | A1 |
20020156471 | Stern et al. | Oct 2002 | A1 |
20020165529 | Danek | Nov 2002 | A1 |
20020193851 | Silverman et al. | Dec 2002 | A1 |
20030004082 | Masschelein et al. | Jan 2003 | A1 |
20030060811 | McDaniel | Mar 2003 | A1 |
20030130575 | Desai | Jul 2003 | A1 |
20030130711 | Pearson | Jul 2003 | A1 |
20030158566 | Brett | Aug 2003 | A1 |
20030199866 | Stern et al. | Oct 2003 | A1 |
20030212393 | Knowlton et al. | Nov 2003 | A1 |
20030216728 | Stern et al. | Nov 2003 | A1 |
20030220635 | Knowlton et al. | Nov 2003 | A1 |
20040000316 | Knowlton et al. | Jan 2004 | A1 |
20040002705 | Knowlton et al. | Jan 2004 | A1 |
20040034346 | Stern et al. | Feb 2004 | A1 |
20040049251 | Knowlton | Mar 2004 | A1 |
20040073079 | Altshuler et al. | Apr 2004 | A1 |
20040143250 | Trembly | Jul 2004 | A1 |
20040186535 | Knowlton | Sep 2004 | A1 |
20040206365 | Knowlton | Oct 2004 | A1 |
20040210214 | Knowlton | Oct 2004 | A1 |
20040230260 | MacFarland et al. | Nov 2004 | A1 |
20040243182 | Cohen et al. | Dec 2004 | A1 |
20040243200 | Turner et al. | Dec 2004 | A1 |
20040249426 | Hoenig et al. | Dec 2004 | A1 |
20050137654 | Hoenig et al. | Jun 2005 | A1 |
20050215987 | Slatkine | Sep 2005 | A1 |
20050251117 | Anderson et al. | Nov 2005 | A1 |
20050251120 | Anderson et al. | Nov 2005 | A1 |
20060020309 | Altshuler et al. | Jan 2006 | A1 |
20060025837 | Stern et al. | Feb 2006 | A1 |
20060036300 | Kreindel | Feb 2006 | A1 |
20060111744 | Makin et al. | May 2006 | A1 |
20060112698 | Cazzini et al. | Jun 2006 | A1 |
20060129209 | McDaniel | Jun 2006 | A1 |
20060151485 | Cronin | Jul 2006 | A1 |
20060161228 | Lach | Jul 2006 | A1 |
20060167498 | DiLorenzo | Jul 2006 | A1 |
20060184205 | Schuler et al. | Aug 2006 | A1 |
20060200213 | McDaniel | Sep 2006 | A1 |
20060206110 | Knowlton et al. | Sep 2006 | A1 |
20060259102 | Slatkine | Nov 2006 | A1 |
20060265034 | Aknine et al. | Nov 2006 | A1 |
20060271028 | Altshuler et al. | Nov 2006 | A1 |
20060276860 | Ferren et al. | Dec 2006 | A1 |
20070010811 | Stern et al. | Jan 2007 | A1 |
20070016032 | Aknine | Jan 2007 | A1 |
20070020355 | Schlebusch et al. | Jan 2007 | A1 |
20070049918 | Van der Weide et al. | Mar 2007 | A1 |
20070060989 | Deem et al. | Mar 2007 | A1 |
20070078290 | Esenaliev | Apr 2007 | A1 |
20070078502 | Weber et al. | Apr 2007 | A1 |
20070179482 | Anderson | Aug 2007 | A1 |
20070179535 | Morrissey et al. | Aug 2007 | A1 |
20070233226 | Kochamba et al. | Oct 2007 | A1 |
20070255274 | Stern et al. | Nov 2007 | A1 |
20070255355 | Altshuler et al. | Nov 2007 | A1 |
20070255362 | Levinson et al. | Nov 2007 | A1 |
20070265614 | Stern et al. | Nov 2007 | A1 |
20070270925 | Levinson | Nov 2007 | A1 |
20080077201 | Levinson et al. | Mar 2008 | A1 |
20080077202 | Levinson | Mar 2008 | A1 |
20080077211 | Levinson et al. | Mar 2008 | A1 |
20080269851 | Deem et al. | Oct 2008 | A1 |
Number | Date | Country |
---|---|---|
0 139 607 | May 1985 | EP |
0 139 607 | May 1985 | EP |
0 370 890 | May 1990 | EP |
WO 8902292 | Mar 1989 | WO |
WO 9207622 | May 1992 | WO |
WO 9641579 | Dec 1996 | WO |
Number | Date | Country | |
---|---|---|---|
Parent | 08904175 | Jul 1997 | US |
Child | 09637923 | US |